AAAAAA
Results: 201-225/860
Authors:
Bruder, MC
Spanhaak, S
Bruijntjes, JP
Michielsen, CPPC
Vos, JG
Kuper, CF
Citation: Mc. Bruder et al., Intestinal T lymphocytes of different rat strains in immunotoxicity, TOX PATHOL, 27(2), 1999, pp. 171-179
Authors:
Mossman, BT
Citation: Bt. Mossman, Environmental pathology: New directions and opportunities, TOX PATHOL, 27(2), 1999, pp. 180-186
Authors:
Calabrese, EJ
Baldwin, LA
Citation: Ej. Calabrese et La. Baldwin, The marginalization of hormesis, TOX PATHOL, 27(2), 1999, pp. 187-194
Authors:
Calabrese, EJ
Baldwin, LA
Citation: Ej. Calabrese et La. Baldwin, Chemical hormesis: Its historical foundations as a biological hypothesis, TOX PATHOL, 27(2), 1999, pp. 195-216
Authors:
Walter, GL
Citation: Gl. Walter, Effects of carbon dioxide inhalation on hematology, coagulation, and serumclinical chemistry values in rats, TOX PATHOL, 27(2), 1999, pp. 217-225
Authors:
Kohgo, T
Iizuka, T
Shindoh, M
Citation: T. Kohgo et al., Pathological evaluation of the effects of intentional disocclusion and overloading occlusion in odontogenesis disorders in N-methylnitrosourea-treated hamsters, TOX PATHOL, 27(2), 1999, pp. 226-232
Authors:
Miyajima, R
Hosoi, M
Yamamoto, S
Mikami, S
Yamakawa, S
Iwata, H
Enomoto, M
Citation: R. Miyajima et al., Eosinophilic granulated cells comprising a tumor in a Fischer rat, TOX PATHOL, 27(2), 1999, pp. 233-236
Authors:
Moore, MA
Tsuda, H
Tamano, S
Hagiwara, A
Imaida, K
Shirai, T
Ito, N
Citation: Ma. Moore et al., Marriage of a medium-term liver model to surrogate markers - A practical approach for risk and benefit assessment, TOX PATHOL, 27(2), 1999, pp. 237-242
Authors:
Alden, CL
Citation: Cl. Alden, Are we talking to the right people?, TOX PATHOL, 27(2), 1999, pp. 243-243
Authors:
Silverman, LR
Khan, KNM
Citation: Lr. Silverman et Knm. Khan, "Have you seen this?" Nonsteroidal anti-inflammatory drug-induced renal papillary necrosis in a dog, TOX PATHOL, 27(2), 1999, pp. 244-245
Authors:
Johnson, CW
Citation: Cw. Johnson, Issues in immunohistochemistry, TOX PATHOL, 27(2), 1999, pp. 246-248
Citation: Mechanisms of Toxicity and Carcinogenesis - July 18-21, 1998, the Gant Conference Center, Aspen, Colorado - Abstracts, TOX PATHOL, 27(2), 1999, pp. 252-265
Authors:
Klingbeil, C
Hsu, DH
Citation: C. Klingbeil et Dh. Hsu, Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use, TOX PATHOL, 27(1), 1999, pp. 1-3
Authors:
Pilaro, AM
Serabian, MA
Citation: Am. Pilaro et Ma. Serabian, Preclinical development strategies for novel gene therapeutic products, TOX PATHOL, 27(1), 1999, pp. 4-7
Authors:
Monteith, DK
Levin, AA
Citation: Dk. Monteith et Aa. Levin, Synthetic oligonucleotides: The development of antisense therapeutics, TOX PATHOL, 27(1), 1999, pp. 8-13
Authors:
Mordenti, J
Thomsen, K
Licko, V
Chen, H
Meng, YG
Ferrara, N
Citation: J. Mordenti et al., Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans, TOX PATHOL, 27(1), 1999, pp. 14-21
Authors:
Black, LE
Bendele, AM
Bendele, RA
Zack, PM
Hamilton, M
Citation: Le. Black et al., Regulatory decision strategy for entry of a novel biologic therapeutic with a clinically unmonitorable toxicity into clinical trials: Pre-IND meetings and a case example, TOX PATHOL, 27(1), 1999, pp. 22-26
Authors:
Serabian, MA
Pilaro, AM
Citation: Ma. Serabian et Am. Pilaro, Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond, TOX PATHOL, 27(1), 1999, pp. 27-31
Authors:
Gossett, KA
Narayanan, PK
Williams, DM
Gore, ER
Herzyk, DJ
Hart, TK
Sellers, TS
Citation: Ka. Gossett et al., Flow cytometry in the preclinical development of biopharmaceuticals, TOX PATHOL, 27(1), 1999, pp. 32-37
Authors:
Levin, S
Friedman, RM
Cortez, E
Hribar, J
Nicholas, M
Schlessinger, S
Fouant, M
Khan, N
Citation: S. Levin et al., Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney, TOX PATHOL, 27(1), 1999, pp. 38-43
Authors:
Maurer, JK
Jester, JV
Citation: Jk. Maurer et Jv. Jester, Use of in vivo confocal microscopy to understand the pathology of accidental ocular irritation, TOX PATHOL, 27(1), 1999, pp. 44-47
Authors:
Gillett, NA
Chan, CM
Citation: Na. Gillett et Cm. Chan, Molecular pathology in the preclinical development of biopharmaceuticals, TOX PATHOL, 27(1), 1999, pp. 48-52
Authors:
Puri, RK
Citation: Rk. Puri, Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma, TOX PATHOL, 27(1), 1999, pp. 53-57
Authors:
Car, BD
Eng, VM
Lipman, JM
Anderson, TD
Citation: Bd. Car et al., The toxicology of interleukin-12: A review, TOX PATHOL, 27(1), 1999, pp. 58-63
Authors:
Danilenko, DM
Citation: Dm. Danilenko, Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor, TOX PATHOL, 27(1), 1999, pp. 64-71